RA Capital Management | Activity

Exit

Crinetics Therapeutics was acquired by Vertex Pharmaceuticals in July 2026.

Crinetics Pharmaceuticals

Crinetics Pharmaceuticals RA Capital Management

racap.comJUL 2026

JUL 2026

Press

Peter Kolchinsky discussed policy constraints limiting biomedical innovation in a media interview.

Kolchinsky: Policy constraints holding back biomedical innovation

RA Capital Management

racap.comJUN 30, 2026

JUN 30, 2026

Exit

Apogee Therapeutics was acquired by AbbVie in June 2026.

Apogee Therapeutics

Apogee Therapeutics RA Capital Management

racap.comJUN 2026

JUN 2026

Exit

Portfolio company Curevo Vaccine was acquired by Eli Lilly in May 2026.

Curevo Vaccine

Curevo Vaccine RA Capital Management

racap.comMAY 2026

MAY 2026

Exit

Portfolio company Ajax Therapeutics was acquired by Eli Lilly in April 2026.

Ajax Therapeutics

Ajax Therapeutics RA Capital Management

racap.comAPR 2026

APR 2026

Exit

Portfolio company Day One Biopharmaceuticals was acquired by Servier in March 2026.

Day One Biopharmaceuticals

Day One Biopharmaceuticals RA Capital Management

racap.comMAR 2026

MAR 2026

Exit

Portfolio company Elektrofi was acquired by Halozyme Therapeutics in November 2025.

Elektrofi

Elektrofi RA Capital Management

racap.comNOV 2025

NOV 2025

Exit

Portfolio company Halda Therapeutics was acquired by Johnson & Johnson in November 2025.

Halda Therapeutics

Halda Therapeutics RA Capital Management

racap.comNOV 2025

NOV 2025

Exit

Portfolio company Cidara Therapeutics was acquired by Merck & Co. in November 2025.

Cidara Therapeutics

Cidara Therapeutics RA Capital Management

racap.comNOV 2025

NOV 2025

Investment

Provided up to $250M structured loan facility ($100M initial) to ARS Pharma alongside OMERS Life Sciences to fund commercialization of neffy needle-free epinephrine nasal spray.

ARS Pharmaceuticals

ARS PharmaceuticalsRA Capital Management

racap.comSEP 30, 2025 prnewswire.com

SEP 30, 2025

Exit

Portfolio company 89bio was acquired by Roche in September 2025.

89bio

89bio RA Capital Management

racap.comSEP 2025

SEP 2025

Exit

Portfolio company Metsera was acquired by Pfizer in September 2025.

Metsera

Metsera RA Capital Management

racap.comSEP 2025

SEP 2025

Exit

Portfolio company Merus was acquired by Genmab in September 2025.

Merus

Merus RA Capital Management

racap.comSEP 2025

SEP 2025

Exit

Portfolio company HilleVax was acquired by Xoma Royalty in August 2025.

HilleVax

HilleVax RA Capital Management

racap.comAUG 2025

AUG 2025

RA Capital Management Activity

Crinetics Therapeutics was acquired by Vertex Pharmaceuticals in July 2026.

Peter Kolchinsky discussed policy constraints limiting biomedical innovation in a media interview.

Apogee Therapeutics was acquired by AbbVie in June 2026.

Portfolio company Curevo Vaccine was acquired by Eli Lilly in May 2026.

Portfolio company Ajax Therapeutics was acquired by Eli Lilly in April 2026.

Portfolio company Day One Biopharmaceuticals was acquired by Servier in March 2026.

Portfolio company Elektrofi was acquired by Halozyme Therapeutics in November 2025.

Portfolio company Halda Therapeutics was acquired by Johnson & Johnson in November 2025.

Portfolio company Cidara Therapeutics was acquired by Merck & Co. in November 2025.

Provided up to $250M structured loan facility ($100M initial) to ARS Pharma alongside OMERS Life Sciences to fund commercialization of neffy needle-free epinephrine nasal spray.

Portfolio company 89bio was acquired by Roche in September 2025.

Portfolio company Metsera was acquired by Pfizer in September 2025.

Portfolio company Merus was acquired by Genmab in September 2025.

Portfolio company HilleVax was acquired by Xoma Royalty in August 2025.